Depression, Neuroplasticity, and Why Your Brain Can Still Change

You've tried the medications. You've waited the six-to-eight weeks, more than once, hoping this would be the antidepressant that finally worked. And you're still here, searching for something that makes sense of why nothing has clicked.

You're not broken. Roughly one in three people with depression don't respond adequately to standard antidepressants, and that's not a personal failing. It may mean your brain needs a different kind of help.

The bottom line: Depression is associated with changes in brain structure and in the brain's ability to form new connections. Treatments that restore that ability, called neuroplasticity, may provide relief when traditional antidepressants haven't, often within hours or days rather than weeks.

What Is Neuroplasticity?

Your brain is not fixed. It's constantly forming new connections, strengthening useful ones, and pruning the ones it doesn't need. This capacity to physically reorganize itself is called neuroplasticity, and it's what allows you to learn, adapt, and recover from injury throughout your entire life.

A 2020 review in Molecular Psychiatry describes neuroplasticity as including both structural changes (the physical shape and number of connections between neurons) and functional changes (how effectively those connections communicate). Both matter in depression.

How Depression Affects Your Brain's Ability to Change

If your mind has felt slower, flatter, or harder to shift, there's a reason that goes beyond mood. Depression involves physical changes in brain structure, including smaller regions involved in thinking and emotion, and fewer connections between neurons.

The areas most affected are the ones you rely on every day. Your hippocampus, which supports memory and emotional regulation, shows volume loss on brain scans in people with depression. Your prefrontal cortex, responsible for focus and decision-making, can lose synaptic connections under chronic stress.

Your amygdala, which processes emotion and social cues, shows changes too. Together, these regions form the core network for how you experience, interpret, and regulate emotion.

BDNF, Stress, and Why You Feel Stuck

One reason depression can feel so hard to shift is that it affects Brain-Derived Neurotrophic Factor, or BDNF. Think of BDNF as fertilizer for brain cells. In depression, BDNF declines in the prefrontal cortex and hippocampus. Chronic stress drives much of that damage by flooding the brain with cortisol, which is directly toxic to neurons in the regions that need plasticity most.

When BDNF drops and cortisol stays elevated, your brain has a harder time forming and maintaining connections. It becomes less adaptable, which can make it feel like you're stuck in the same patterns no matter how hard you try.

The Evidence That Plasticity Can Return

Researchers have measured this directly. A 2013 study compared brain plasticity in people with depression to healthy controls using targeted brain stimulation. People with depression showed significantly reduced capacity to form new connections.

That reduced plasticity is not permanent. A follow-up study found that it improved after effective treatment, which is encouraging: restoring your brain's flexibility appears to be directly connected to feeling better.

Why Traditional Antidepressants May Not Be Enough

Most antidepressants work by adjusting serotonin or norepinephrine levels. These include selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs), the most commonly prescribed classes. This approach rests on the older idea that low levels of these chemical messengers drive depression.

If serotonin explanations never fully matched your experience, there's a reason. A 2017 review concluded that the traditional neurobiological theories of depression don't account for the full picture. The reality is more complex than one chemical being too low.

SSRIs do promote some neuroplasticity over time, but the process is slow. The largest real-world antidepressant study ever conducted, the STAR*D trial, found that it took an average of six weeks for people to respond and nearly seven weeks to reach remission. Only about one-third of people achieved remission on their first antidepressant.

For people with treatment-resistant depression, the neuroplasticity-related pathways may be especially affected. One study identified a distinct subtype of treatment-resistant depression linked to impaired plasticity mechanisms. If SSRIs haven't worked for you, the issue may not be that you need more serotonin. It may be that your brain needs a treatment that targets plasticity more directly.

How Ketamine May Help Restore Neuroplasticity

Among the approaches that target brain plasticity directly, ketamine is the most studied for its rapid effects. Ketamine therapy targets your brain's glutamate system rather than serotonin. The biology is different from traditional antidepressants, and for people who've been waiting weeks or months for medications to take effect, that difference is significant.

Stage 1: Releasing the brake. Ketamine temporarily lifts one of the brain's braking signals. The result is a glutamate burst, the brain's primary activation signal.

Stage 2: Growth factor release. The glutamate surge triggers a rapid increase in BDNF. Unlike SSRIs, which take weeks to raise BDNF levels, ketamine can do this within hours. People who responded to treatment showed elevated BDNF at four hours post-treatment.

Stage 3: New connections form. BDNF provides the building blocks of new brain connections. A single dose of ketamine increased synapses and synaptic function in the prefrontal cortex soon after treatment. Effects lasted at least 72 hours. Research also found that ketamine reversed stress-related damage to synaptic connections in that region.

What the Clinical Evidence Shows

The clinical results reflect the same biology. The landmark trial at the National Institute of Mental Health found that people with treatment-resistant depression showed significant improvement by 110 minutes. Roughly 7 in 10 showed meaningful improvement the following day.

A 2023 meta-analysis of 49 randomized controlled trials with over 3,200 participants found that ketamine was associated with higher response and remission rates compared to control conditions. For context, traditional antidepressant response rates in treatment-resistant depression fall below 20%. Ketamine response rates exceed 50%.

What Recovery Actually Looks Like

Clinical trials measure symptom reduction on standardized scales. But what does improvement actually feel like?

Recent research suggests that restoring plasticity doesn't directly lift mood on its own. What it does is make your brain more open to change. The medication creates the conditions; what you do during that window, through therapy, new habits, and environment, shapes where the change goes.

People often describe the shift as the volume turning down. The constant background noise of dread or emptiness doesn't vanish, but it quiets enough to function. You might notice you can get out of bed without the usual negotiation. Ruminative thought loops that seemed automatic become interruptible. It's closer to remembering what "okay" felt like before depression made you forget than to euphoria.

The experience varies from person to person, but the pattern is consistent: space where there wasn't space before.

Why Integration Matters

The neuroplastic window following ketamine doesn't stay open indefinitely. Research suggests it's time-limited, which is why scheduling integration therapy during that period matters. The medication opens a door; therapy helps you walk through it. A 2017 trial found that structured psychotherapy after ketamine helped sustain the antidepressant effects longer than ketamine alone.

Lifestyle factors support the same process. Exercise activates BDNF pathways that overlap with ketamine's mechanism. Sleep, stress management, and small steps toward re-engaging with your life consolidate the new connections your brain is building.

Structured integration work can give that process direction.

Safety and Honest Limitations

Ketamine therapy isn't right for everyone. Common side effects include dissociation, nausea, dizziness, and temporary increases in blood pressure. Most are short-term and resolve within hours.

More serious concerns include bladder damage with chronic use and potential for dependency. Ketamine is a Schedule III controlled substance and its use for psychiatric conditions is off-label. People with uncontrolled high blood pressure, a history of psychosis, unstable heart disease, active substance-use disorder, or pregnancy may not be good candidates for this treatment.

Durability is worth understanding upfront. Effects from a single session typically last one to two weeks, though repeated sessions can extend that benefit; one trial found that multiple infusions doubled response compared to a single dose. Ketamine can open a window for change. It is not a one-time fix.

How Innerwell's At-Home Ketamine Therapy Works

If you've read this far, you're probably wondering what trying this would actually look like.

Innerwell offers at-home ketamine therapy that pairs sublingual tablets with licensed therapeutic support. This isn't just a prescription. It's comprehensive mental health care. Every step includes clinical guidance from Master's and Doctoral level therapists, not unlicensed guides.

The process:

1. Evaluation: A thorough psychiatric assessment to determine whether ketamine therapy is appropriate for your specific situation, including medical history, current medications, and treatment goals.
2. Delivery: Sublingual ketamine tablets shipped to your home from a licensed pharmacy, which eliminates the time and cost of IV clinic visits.
3. Preparation and integration: Therapy sessions before and after each ketamine experience so you can make the most of the neuroplastic window ketamine creates.
4. Ongoing monitoring: Regular check-ins with your care team to track progress and adjust treatment as needed.

Pricing: $54–75 per session with insurance; $83–125 per session for self-pay, compared to $150–400 or more at IV clinics.

Program outcomes: 69% reduction in depression symptoms after 10 weeks. 60% reduction in anxiety symptoms. 87% of people see improvement within four weeks, with an average rating of 4.7 out of 5

Take the free assessment to see if ketamine therapy might be right for you.

Frequently Asked Questions

What does a ketamine session actually feel like?

Most people experience some dissociation during a session, which can feel like floating, dreamlike imagery, or a sense of detachment from your usual thought patterns. Some describe it as strange but not unpleasant. The effects typically resolve within one to two hours. Having a calm, familiar environment and a clear intention for the session can help. Innerwell's therapists prepare you for what to expect beforehand.

Can I take ketamine while on other antidepressants?

In many cases, yes. Ketamine works through a different mechanism than SSRIs and SNRIs, so it can often be used alongside existing medications. Innerwell's clinical team reviews your full medication list during the initial evaluation to check for interactions. Some medications, particularly monoamine oxidase inhibitors (MAOIs) and certain benzodiazepines, may need adjustment before starting.

Is the "chemical imbalance" theory of depression wrong?

A 2022 review found no consistent evidence that depression is caused by low serotonin. SSRIs can still help many people, but the picture is broader than a single neurotransmitter. Depression also involves impaired neuroplasticity, disrupted stress signaling, and changes in brain structure. That broader picture explains why some people respond to conventional medication and others need a different approach, such as treatments that target plasticity directly.